Ignite Creation Date:
2025-12-24 @ 12:05 PM
Ignite Modification Date:
2025-12-27 @ 9:33 PM
Study NCT ID:
NCT00760461
Status:
TERMINATED
Last Update Posted:
2017-08-18
First Post:
2008-09-24
Is Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Domperidone in Refractory Gastroparesis
Sponsor:
Yale University
Organization:
Study Overview
Official Title:
Domperidone in Refractory Gastroparesis
Status:
TERMINATED
Status Verified Date:
2017-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Enrolled subjects were unable to receive drug from dispensing pharmacy.
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The primary objective of this study is to prescribe oral domperidone for patients with gastroparesis who have failed or suffered adverse effects from standard medical therapy.
Detailed Description:
None
Study Oversight
Has Oversight DMC:
False
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?: